Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Biologic therapies, such as lenalidomide, may stimulate the immune system in different ways
and stop cancer cells from growing. Idelalisib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. This phase I trial studies the side
effects and the best dose of lenalidomide when giving together with idelalisib in treating
patients with recurrent follicular lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Celgene Corporation Gilead Sciences National Cancer Institute (NCI)